Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-10-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于2025年第三季度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the third quarter of 2025. It contains detailed financial data such as revenue, net profit, cash flow, and segment information for the quarter and year-to-date periods. It also includes operational data about store openings and closures during the period. The document length is 2782 characters, which is relatively short but contains substantive financial data and analysis for a quarterly period. It is not merely an announcement of a report publication but provides actual financial figures and business metrics. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-29 Chinese
益丰药房关于募集资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of entrusted financial management of raised funds, detailing the purchase and redemption of financial products using idle raised funds. It includes specific product names, amounts, dates, risk warnings, and the company's measures to manage these investments. The document is relatively short (3578 characters) and focuses on updates about financing activities related to the use of raised funds, rather than presenting comprehensive financial statements or results. There is no indication of it being a full financial report, audit report, or earnings release. The content fits best with a Capital/Financing Update, as it provides updates on the company's financing activities and capital management related to raised funds and entrusted financial products.
2025-10-27 Chinese
益丰药房关于为控股子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from a company regarding the provision of guarantees for its controlling subsidiary. It details the guarantee amount, the parties involved, the decision-making process, financial data of the subsidiary, and the rationale and board opinions on the guarantee. The document is titled as an "announcement" and contains no comprehensive financial statements or detailed financial performance analysis. It is a regulatory announcement about a financing-related guarantee activity rather than a full financial report or earnings release. The document length is 3212 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it relates to updates on company financing activities and guarantees provided.
2025-10-24 Chinese
益丰药房关于2022年限制性股票激励计划预留授予股份第二次解除限售暨上市公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the unlocking and listing of restricted shares under a 2022 restricted stock incentive plan. It details the approval and implementation of the stock incentive plan, the unlocking conditions, the number of shares unlocked, and the listing date. It includes specific dates, share quantities, and compliance with regulatory requirements. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement about the unlocking and listing of restricted shares related to a stock incentive plan. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share unlocking and listing, not a full report or financial statement.
2025-10-21 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2022年限制性股票激励计划预留授予股份第二次解除限售暨上市相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the second unlocking and listing of reserved shares under a 2022 restricted stock incentive plan of a company. It discusses legal compliance, approval procedures, unlocking conditions, and stock structure changes related to the stock incentive plan. It is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a capital market event involving stock incentives and share unlocking. This type of document is best classified under Regulatory Filings (RNS) as it does not fit the other specific categories like Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) exactly, since it is a legal opinion on stock incentive unlocking and listing rather than a direct announcement of capital changes or financing. The document length is about 4953 characters, and it contains detailed legal analysis and opinion rather than just an announcement or summary. Therefore, the best fit is Regulatory Filings (RNS).
2025-10-21 Chinese
益丰药房关于不向下修正“益丰转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 益丰大药房连锁股份有限公司 regarding the decision not to downward adjust the conversion price of its convertible bonds (益丰转债). It details the bond issuance, the conditions triggering price adjustments, and the board's resolution not to adjust the conversion price despite the triggering event. The document is a formal disclosure about bond terms and board decisions related to convertible bond pricing, not a financial report, earnings release, or management discussion. It is a regulatory announcement about capital structure and bond terms, specifically about convertible bond price adjustment rights and decisions. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2520 characters, which is typical for an announcement rather than a full report. No financial statements or detailed financial analysis are included, so it is not an Annual Report or Interim Report. It is not a voting result announcement or a proxy statement, but a corporate financing update regarding convertible bond terms and board decisions.
2025-10-15 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.